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Gregory L. Moneta, MD, Section EditorTen-Year Stroke Prevention after Successful Carotid Endarterectomy
for Asymptomatic Stenosis (ACST-1): A Multicentre Randomised
Trial
Halliday A, Harrison M, Hayter E, Asymptomatic Carotid Surgery Trial
(ACST) Collaborative Group. Lancet 2010;376:1074-84.
Conclusion: Successful carotid endarterectomy (CEA) in asymptom-
atic patients aged 75 years reduces 10-year risk of stroke. Half of the risk
reduction is in the reduction of disabling or fatal strokes.
Summary: From 1993 to 2003, the Asymptomatic Carotid Surgery
Trial (ACST-1) randomly assigned patients to immediate CEA or deferral of
a carotid procedure until a more definitive indication arose. Patients were
followed-up until 2006 to 2008. Median-term results of this trial were
reported in 2004 (Lancet 2004;363:1491-502). In this article, the authors
describe 10-year results of the ACST trial and delineate benefits by partici-
pant’s medical treatment and characteristics.
There were 1560 patients assigned to the immediate CEA group and
1560 patients assigned to the group with deferral of any carotid procedure.
Proportions operated on while still asymptomatic were 89.7% vs 4.8% at 1
year and 92.1% vs 16.5% at 5 years. The 30-day stroke and death risk
perioperatively was 3.0% (95% confidence interval [CI], 2.4-3.9). In 1979
CEAs there were 26 nondisabling strokes plus 34 disabling or fatal periop-
erative events. When perioperative events and nonstroke mortality were
excluded, stroke risk (immediate vs deferred CEA) was 4.1% vs 10.0% at 5
years for a gain of 5.9% (95% CI, 4.0-7.8%) and 10.8% vs 16.9% at 10 years
for a gain of 6.1% (95% CI, 2.7%- 9.4%); the ratio of stroke incidence rates
was 0.54 (95% CI 0.43-0.68, P  .0001). A fatal or disabling stroke
occurred in 62 vs 104 and nondisabling stroke in 37 vs 84. When perioper-
ative events and strokes were combined, net risks were 6.9% vs 10.9% at 5
years for a 4.1% gain (95% CI, 2.0%-6.2%) and 13.4% vs 17.9% at 10 years for
a 4.6% gain (95% CI, 1.2%-7.9%). Most patients throughout the study were
receiving antithrombotic and antihypertensive therapy, and medications
were similar in both groups. There were significant net benefits for patients
both receiving and not receiving lipid-lowering therapy and for both men
and women up to age 75 years entering the trial.
Comment: The study provides evidence for long-term effectiveness
of CEA for stroke prevention in patients with initially asymptomatic
high-grade carotid stenosis but suggests that potential long-term benefits
of CEA are limited in those with a life expectancy of 10 years.
Compliant patients with effective antithrombotic, lipid-lowering and
antihypertensive therapy and little likelihood of death from other causes
in 10 years have a predicted absolute 10-year stroke reduction of about
5%, suggesting about 20 endarterectomies will be required to avoid 1
stroke at 10 years. Cost effectiveness vs medical effectiveness with such an
approach will be debated. Basically, the report indicates that for other-
wise healthy men and women aged 75 years, there is a net but very
modest benefit in stroke reduction for prophylactic CEA in patients with
asymptomatic high-grade ICA stenosis.
A Statewide Consortium of Surgical Care: A Longitudinal Investiga-
tion of Vascular Operative Procedures at 16 Hospitals
Henke PK, Kubus J, Englesbe MJ, et al. Surgery 2010;148:883-92.
Conclusion: Timely feedback of data from a statewide quality of care
consortium can be associated with decreased morbidity over a relatively
short follow-up period in vascular surgical patients.
Summary:With the publication of the Institute of Medicine landmark
report, To Err is Human in 1999, there has been increased emphasis on
identifying processes to improve outcomes and quality of care. There has
also been increased oversight from both government and nongovernmental
quality organizations. These include national bodies, such as the National
Surgical Quality Improvement Program (NSQIP), and more regional qual-
ity of care consortiums. A statewide volunteer group of hospitals in Michi-
gan, called the Michigan Surgical Quality Consortium (MSQC), consists
primarily of nonteaching hospitals that use the NSQIP data abstraction and
reporting format. MSQC feeds back information to individual hospitals.
Quarterly conferences review evidence-based practices such as venous
thromboembolism prophylaxis, pulmonary complications, and transfusions.
The authors of this study sought to determine whether improvements in
morbidity or mortality have occurred since the inception of the MSQC
program. The study involved 16 hospitals that report cases of open vascular
interventions. Sampling was done consistent with NSQIP with data ab-
stracted by on-site trained nurses using predefined and validated preopera-
tive, perioperative, and postoperative variables. Follow-up was 30 days.
Emergent and outpatient cases were excluded. To assess the effectiveness of
246the MSQC consortium feedback on morbidity and mortality, the authors
compared outcomes over the course of two periods: era 1, from April 2005
to March 2007, and era 2, from April 2007 to March 2008.
There were 2452 cases in era 1 and 3409 in era 2. Cases were similar
between the two eras, with a mean patient age of 68 years, 61% were men,
and there were a mean number of relative value units of 21 per patient.
Distribution of current procedural terminology (CPT) codes was also simi-
lar. Comparing era 1 with era 2, duration of stay and operative time
decreased by 15% and 11%, respectively. The 30-day mortality rate was no
different, at 2.7% vs 2.5% (PNS). Morbidity decreased from 15.8% in era
1 to 13.8% in era 2 (P .2). Decreases were noted particularly in sepsis and
pulmonary complications. Modifiable variables (those able to be altered by
the surgeon) for morbidity included increased length of operation (odds
ratio [OR], 1.04; 95% confidence interval [CI], 1.003-1.005; P  .0001),
hypertension (OR, 1.46; 95% CI, 1.03-2.1; P .03), and blood transfusion
(OR, 2.8; 95% CI, 2.04- 3.88; P  .0001). Anemic patients (hematocrit
30) who received a transfusion were less likely to suffer morbidity (OR,
0.56; 95% CI, 0.47-0.67; P .0001). A cost analysis indicated a cost savings
of $172 for payers per vascular case in era 2 vs era 1.
Comment: The study indicates that a statewide surgical hospital con-
sortium using the NSQIP platform can produce significant but modest
decreases in morbidity over a relatively short time. This decrease in mor-
bidity translated into a significant projected cost savings even though the
cost of NSQIP is about $135,000. Financial support of MSQC, a
“pay-for-participation” system, is primarily provided by the Blues of
Michigan. There is currently an effort to establish regional vascular
consortiums nationwide. The cost of collecting and analyzing this type of
data is not insignificant, and perhaps efforts should be made for these
regional consortiums to be supported by insurance companies rather
than individual physicians and hospitals.
Association of Colony-Forming Units With Coronary Artery and Ab-
dominal Aortic Calcification
Cheng S, Cohen KS, Shaw SY. Circulation 2010;122:1176-82.
Conclusion: Lower numbers of colony-forming units of endothelial
progenitor cells are associated with a higher burden of subclinical athero-
sclerosis in the aorta and coronary arteries.
Summary: Calcified plaques of the aorta and coronary arteries are
considered markers of atherosclerosis and predictive of future cardiovascular
events (Detrano R, N Eng J Med 2008;358:1336-45). Some peripherally
circulating cell populations, termed endothelial progenitor cells (EPCs),
appear to have endothelial angiogenic and reparative properties. A decreased
EPC number may result in an increased risk of adverse cardiovascular
outcomes (Circulation 2005;111:2981-7). The authors examined a poten-
tial link between EPC number and atherosclerosis by correlating EPC
numbers with arterial calcification. They reasoned an association of EPCs
with arterial calcification would support the hypothesis that depletion of
EPCs contributes to progression from subclinical endothelial dysfunction to
cardiovascular disease in humans.
Patients for this study were 889 participants (55% women; mean age,
65 years) from the Framingham Heart Study. All were initially free of
clinically apparent cardiovascular disease and underwent EPC phenotyping
with a colony-forming unit essay and cell surface markers. Multidetector
computed tomography noncontrast scanning was used to detect subclinical
atherosclerosis in the coronary arteries and abdominal aorta. Across decreas-
ing tertiles of colony-forming units there was an increase in median coronary
artery calcification and abdominal aortic calcification scores. Adjusting for
traditional cardiovascular risk factors in multivariant analysis, each 1-SD
increase in colony-forming units was associated with an approximately 16%
decrease in coronary artery calcification (P  .02) and a 17% decrease in
abdominal aortic calcification (P  .03). Neither CD34/KDR nor
CD34 variation (cell surface markers) correlated with differences in coro-
nary or aortic calcification.
Comment:The results are consistent with the theory that EPC colony-
forming units and CD34-related cells represent different functional types
of EPCs. Each may have distinct roles in mediating the vascular response to
atherogenic exposures. A decreased angiogenic potential reflected in de-
creased colony-forming units of EPC cells could contribute, in some way, to
development of human atherosclerosis. Stimulation of EPC production may
someday serve as potential therapy in patients with atherogenic risk factors.
